A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 01 Mar 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 01 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.